Cardio · Renal · Metabolic
One virtual ward for the patients who use most of the hospital.
Renvia unifies remote monitoring for heart failure, chronic kidney disease and type-2 diabetes into a single clinician-in-the-loop pathway — designed to reduce avoidable admissions and stabilise complex, comorbid patients at home.
- Clinician-in-the-loop
- UK GDPR & DTAC-aligned
- Built with NHS clinicians
Virtual ward · Live cohort
142 patients monitored
SpO₂
97%
BP
128/82
eGFR
42
Escalation triggered · Bed 07
Weight ↑ 1.8 kg in 48h · reviewed by CN Adeyemi · titration adjusted
Built with NHS cardiology & renal clinicians
Clinical safety per DCB0129 / DCB0160
UK GDPR · DSP Toolkit · DTAC-aligned
Founder-published cardio-renal research
The problem
Heart, kidney and metabolic disease share patients — but not pathways.
Roughly one in three adults with type-2 diabetes has chronic kidney disease, and heart failure decompensation is the leading cause of unplanned readmission in this cohort. Yet clinics, medications and monitoring still sit in separate silos.
Read the clinical rationale1 in 3
T2D patients also have CKD
~25%
of HF admissions readmit within 30 days
£2bn+
annual NHS cost of avoidable HF admissions
3×
mortality risk when cardio-renal-metabolic conditions coexist
How Renvia works
A four-step pathway, not another dashboard.
Enrol & baseline
Clinician onboards patient with paired devices, medication list and safety plan.
Passive monitoring
Weight, BP, SpO₂, glucose and symptoms stream into a single cardio-renal-metabolic view.
Clinician-in-the-loop
Rule-based triggers surface early decompensation; a named clinician reviews every escalation.
Titrate & prevent
Diuretic and guideline-directed therapy adjustments are actioned before admission is needed.
Who it's for
Built for the organisations carrying the risk.
NHS ICBs & trusts
Deploy Renvia as a virtual ward extension for heart failure, CKD and diabetes populations to reduce non-elective admissions.
Private hospital groups
Offer coordinated post-discharge and long-term monitoring as a differentiated service line for insured members.
Insurers & payers
Improve outcomes and lower cost per member per month for high-utiliser cardio-renal-metabolic cohorts.
Evidence & clinical model
Grounded in the founder's published cardio-renal research.
Renvia's pathway design reflects peer-reviewed work on cardio-renal-metabolic comorbidity, guideline-directed medical therapy and remote titration — not a repackaged consumer wearable.
See the clinical modelPeer-reviewed
Founder-published cardio-renal research
Guideline-aligned
ESC / NICE / KDIGO pathways
Safety-first
DCB0129 / DCB0160 clinical safety
Outcomes-led
Admission avoidance & titration KPIs
Stay informed
Clinical updates for cardio-renal-metabolic teams.
Occasional updates on our clinical model, deployments and published research. No marketing, no more than once a month.
Start a conversation
See Renvia inside your pathway.
A 30-minute walkthrough with our clinical lead — no patient data, no obligation.